Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,000.00

Posted by Alphonse Anthony on Jul 24th, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective lifted by Guggenheim from $995.00 to $1,000.00 in a report published on Tuesday,Benzinga reports. Guggenheim currently has a buy rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other research reports. HSBC reduced their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Leerink Partners reiterated a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Barclays reduced their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $787.88.

View Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Up 0.1%

Shares of Regeneron Pharmaceuticals stock opened at $651.91 on Tuesday. The stock has a fifty day simple moving average of $636.62 and a 200 day simple moving average of $714.85. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $821.11. The company has a market capitalization of $68.92 billion, a P/E ratio of 15.88, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same period last year, the business posted $8.22 earnings per share. Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Lockheed Martin Investment Management Co. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $2,702,000. Asio Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $3,422,000. Robeco Institutional Asset Management B.V. lifted its position in Regeneron Pharmaceuticals by 116.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after buying an additional 140,966 shares during the last quarter. National Pension Service lifted its position in Regeneron Pharmaceuticals by 29.8% in the fourth quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after buying an additional 82,853 shares during the last quarter. Finally, AE Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 36.7% during the fourth quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company’s stock worth $4,226,000 after buying an additional 1,470 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Several articles say Regeneron is expected to beat second-quarter earnings estimates, which could reinforce confidence ahead of the company’s upcoming report. Analysts cited stronger-than-expected fundamentals as a reason for optimism. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Positive Sentiment: Guggenheim reportedly raised its price target on Regeneron to $1,000, a sign that at least one Wall Street firm remains very constructive on the company’s long-term prospects. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
Neutral Sentiment: More pre-earnings coverage suggests analysts expect earnings to decline year over year, so the upcoming report will need to show strong execution to keep sentiment positive. Here’s What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report
Negative Sentiment: A wave of class-action lawsuit alerts and deadline reminders is weighing on sentiment, with allegations tied to disclosures around a Phase III Fianlimab-Libtayo melanoma trial and claims that risks were understated. SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
Negative Sentiment: Multiple law firms are urging investors to join securities fraud litigation, highlighting the earlier sharp share-price drop after the failed Phase 3 trial announcement and keeping legal overhang front and center. REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit – Investors With Losses May Contact Levi & Korsinsky

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.